Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA proposes special controls for 11 device types

This article was originally published in The Gray Sheet

Executive Summary

FDA is proposing to amend its regulations for 11 types of neurological and physical medicine devices to establish special controls, including guidance and restrictions on device sales, to help mitigate risks associated with the Class II devices. FDA is proposing to exempt six of the device types from 510(k) pre-market submissions requirements, provided they follow the indicated special controls: electroconductive media, cutaneous electrodes, limited-output transcutaneous electrical nerve stimulators for pain relief, limited-output transcutaneous electrical stimulators for aesthetic purposes, limited-output powered muscle stimulators for rehabilitation, and limited-output powered muscle stimulators for muscle conditioning. Comments on both the April 5 1proposed rule and draft special controls guidance documents are due July 5

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel